

**TERMINAL DISCLAIMER TO OBTAIN A DOUBLE PATENTING  
REJECTION OVER A "PRIOR" PATENT**Docket Number (Optional)  
1973 US

In re Application of:

Application No.: 10/344,881

Filed: February 14, 2003

For: Method Of Treating Angiogenesis-Treated Disorders Using Benzoyl Phenylacetic Acid

The owner\*, Alcon, Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term **prior patent** No. \_\_\_\_\_ as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said **prior patent** is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 40,526

Teresa J. Schultz  
Signature

20 March 06  
Date

Teresa J. Schultz  
Typed or printed name

817-551-4321  
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

03/22/2006 DEMMANU1 00000007 501051 09929381

02 FC:1814 130.00 DA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Michael A. KAPIN et al.

Serial No. 09/929,381 (Conf. #1047)

Filed: 13 August 2001

Examiner: R. Cook

Group Art Unit: 1614

For: METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS

**TRANSMITTAL OF FEE UNDER 37 C.F.R. §1.20(d)**

Mail Stop af  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

A terminal disclaimer has been filed herewith. Please charge the \$130.00 fee required under 37 C.F.R. §§ 1.321(b) and 1.20(d) to Deposit Account No. 501051. A duplicate of this paper is attached.

Respectfully submitted,

ALCON RESEARCH, LTD.

20 March 06

Date

Teresa J. Schultz

Teresa J. Schultz  
Reg. No. 40,526

Address for Correspondence:  
Teresa J. Schultz  
Alcon Research, Ltd.  
R&D Counsel Q-148  
6201 South Freeway  
Fort Worth, TX 76134-2099  
Phone: (817) 551-4321

Attorney Docket: 1972 US